Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Publications
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Publications
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Avacta Academy | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

News

09 Jul 2026

Accelerated Amortized Payment of Convertible Bond Installment

Investors
08 Jul 2026

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors 

Investors
25 Jun 2026

Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference

Investors | Therapeutics
25 Jun 2026

Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer

Investors | Therapeutics
23 Jun 2026

Result of AGM

Investors
22 Jun 2026

Year-to-date business update ahead of Annual General Meeting

Investors
18 Jun 2026

Avacta Academy – Episode 3

Avacta Academy | Therapeutics
05 Jun 2026

Oversubscribed Strategic Equity Fundraise of £9 million

Investors
01 Jun 2026

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

Investors | Therapeutics
29 May 2026

Posting of Annual Report and Notice of AGM

Investors

Posts navigation

Older posts
Avacta Therapeutics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3911 0353

Investor Enquiries

Cohesion Bureau

 

Email

Twitter | Linkedin

©2026 Avacta Therapeutics. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.